Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | ACAT1 | P24752 | 1/20 | 1.00 |
| ▸ | SOAT1 | P35610 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9497923 | 1.00 | KDM4E (1.00) | KDM4ETP53CYP3A4MAPTALOX15 | |
| SCHEMBL9498208 | 1.00 | KDM4E (1.00) | KDM4ETP53CYP3A4MAPTALOX15 | |
| SCHEMBL9497994 | 1.00 | KDM4E (1.00) | KDM4ETP53CYP3A4MAPTALOX15 | |
| SCHEMBL9498202 | 0.93 | KDM4E (0.86) | KDM4ETP53CYP3A4MAPTALOX15 | |
| SCHEMBL9498193 | 0.93 | KDM4E (0.86) | KDM4ETP53CYP3A4MAPTALOX15 | |
| SCHEMBL9500112 | 0.93 | KDM4E (0.86) | KDM4ETP53CYP3A4MAPTALOX15 | |
| SCHEMBL9500118 | 0.93 | KDM4E (0.86) | KDM4ETP53CYP3A4MAPTALOX15 | |
| SCHEMBL16589150 | 0.87 | KDM4E (0.77) | KDM4ETP53CYP3A4MAPTALOX15 | |
| SCHEMBL26206292 | 0.87 | KDM4E (0.77) | KDM4ETP53CYP3A4MAPTALOX15 | |
| SCHEMBL10685098 | 0.85 | KDM4E (0.72) | KDM4ETP53CYP3A4MAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024098005-A1 | COMPOSITION COMPRISING GLP-1 RECEPTOR AGONIST AND ACAT INHIBITOR | EFIL BioScience Inc. (KR) | 2024-05-10 | — | — | WO | claimed |
| US-20240148833-A1 | COMPOSITION COMPRISING GLP-1 RECEPTOR AGONIST AND ACAT INHIBITOR | EFIL BioScience Inc. (KR) | 2024-05-09 | — | — | US | claimed |
| US-20230302021-A1 | COMPOSITIONS AND METHODS FOR TREATING CASTRATION-RESISTANT PROSTATE CANCER | PURDUE RESEARCH FOUNDATION | 2023-09-28 | — | — | US | claimed |
| WO-2023183843-A1 | COMBINATION THERAPY FOR TREATING CASTRATION-RESISTANT PROSTATE CANCER | PURDUE RESEARCH FOUNDATION (US) | 2023-09-28 | — | — | WO | claimed |
| US-20230285333-A1 | COMPOSITIONS AND METHODS FOR CONTROLLING FOOD INTAKE OF ANIMAL | PURDUE RESEARCH FOUNDATION | 2023-09-14 | — | — | US | claimed |
| US-20230270702-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPEPHAGIA | PURDUE RESEARCH FOUNDATION | 2023-08-31 | — | — | US | claimed |
| EP-2453926-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | The Regents of the University of California (US) | 2012-05-23 | — | — | EP | claimed |
| WO-2011008996-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-20 | — | — | WO | claimed |
| US-20100183598-A1 | METHODS OF TREATING CARDIOVASCULAR DISORDERS | CAROLUS THERAPEUTICS, INC. (US) | 2010-07-22 | — | — | US | claimed |
| WO-2010056910-A2 | METHODS OF TREATING CARDIOVASCULAR DISORDERS | CAROLUS THERAPEUTICS, INC. (US) | 2010-05-20 | — | — | WO | claimed |
| EP-0858336-B1 | METHOD AND PHARMACEUTICAL COMPOSITION FOR REGULATING LIPID CONCENTRATION | WARNER LAMBERT CO (US) | 2006-12-20 | — | — | EP | claimed |
| US-6143755-A | DRUGS FOR RESTORATION OF ENDOGENOUS VASCULAR ACTIVITIES AS ANTICOAGULANTS AND VASODILATION | WARNER-LAMBERT COMPANY (US) | 2000-11-07 | — | — | US | claimed |
| US-6124309-A | ADMINISTERING ACYLCOENZYME A:CHOLESTEROL ACYLTRANSFERASE INHIBITOR AND HYDROXY-3-METHYLGLUTARYL/3-/ COENZYME A REDUCTASE INHIBITOR | WARNER-LAMBERT COMPANY (US) | 2000-09-26 | — | — | US | claimed |
| US-6093719-A | ADMINISTERING THERAPEUTICALLY EFFECTIVE AMOUNTS OF ACYL-COA CHOLESTEROL O-ACYLTRANSFERASE (ACAT) INHIBITOR AND AN HMG-COA REDUCTASE INHIBITOR; FOR PATIENTS WITH OR AT RISK OF DEVELOPING ISCHEMIC SYNDROMES | WARNER-LAMBERT COMPANY (US) | 2000-07-25 | — | — | US | claimed |
| CN-1201389-A | Methods and pharmaceutical compositions for modulating lipid concentrations | WARNER LAMBERT CO (US) | 1998-12-09 | — | — | CN | claimed |
| EP-0858336-A1 | METHOD AND PHARMACEUTICAL COMPOSITION FOR REGULATING LIPID CONCENTRATION | WARNER-LAMBERT COMPANY (US) | 1998-08-19 | — | — | EP | claimed |
| WO-1997016184-A1 | METHOD AND PHARMACEUTICAL COMPOSITION FOR REGULATING LIPID CONCENTRATION | WARNER-LAMBERT COMPANY (US) | 1997-05-09 | — | — | WO | claimed |
| EP-0283742-B1 | FATTY ACID AMIDES AS INHIBITORS OF ACYL-COA: CHOLESTEROL ACYLTRANSFERASE | WARNER-LAMBERT COMPANY (US) | 1993-05-26 | — | — | EP | claimed |
| US-4716175-A | INHIBITION OF INTESTINAL ABSORPTION OF CHOLESTEROL | WARNER-LAMBERT COMPANY (US) | 1987-12-29 | — | — | US | claimed |
| EP-3266457-B1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | SHIRE HUMAN GENETIC THERAPIES (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4424363-B1 | METHODS FOR INCREASING GROWTH IN PEDIATRIC SUBJECTS HAVING CHOLESTATIC LIVER DISEASE | MIRUM PHARMACEUTICALS INC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12599602-B2 | Methods for treating cholestasis | MIRUM PHARMACEUTICALS, INC. | 2026-04-14 | — | — | US | disclosed |
| US-20260091010-A1 | COMPOSITIONS AND METHODS FOR MANAGING REBOUND OF BODY WEIGHT AND METABOLIC PARAMETERS | EFIL BIOSCIENCE INC (KR) | 2026-04-02 | — | — | US | disclosed |
| US-12576079-B2 | Methods for treating cholestasis | MIRUM PHARMACEUTICALS, INC. | 2026-03-17 | — | — | US | disclosed |
| US-20250282808-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250281482-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2025-09-11 | — | — | US | disclosed |
| US-12350267-B2 | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-12274681-B2 | Compositions and methods for reducing skin fat | PURDUE RESEARCH FOUNDATION (US) | 2025-04-15 | — | — | US | disclosed |
| US-12274682-B2 | Compositions and methods for controlling food intake of animal | PURDUE RESEARCH FOUNDATION (US) | 2025-04-15 | — | — | US | disclosed |
| US-12257217-B2 | Compositions and methods for treating hyperphagia in prader-willi syndrome | PURDUE RESEARCH FOUNDATION (US) | 2025-03-25 | — | — | US | disclosed |
| CN-114652816-B | Compositions containing HC-HA/PTX3 complexes and methods of use thereof | 生物组织控股公司 | 2025-03-14 | — | — | CN | disclosed |
| EP-4464376-A2 | GENOTYPE AND DOSE-DEPENDENT RESPONSE TO AN ASBTI IN PATIENTS WITH BILE SALT EXPORT PUMP DEFICIENCY | Mirum Pharmaceuticals, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| EP-4424363-A2 | METHODS FOR INCREASING GROWTH IN PEDIATRIC SUBJECTS HAVING CHOLESTATIC LIVER DISEASE | Mirum Pharmaceuticals, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-3923943-B1 | GENOTYPE AND DOSE-DEPENDENT RESPONSE TO AN ASBTI IN PATIENTS WITH BILE SALT EXPORT PUMP DEFICIENCY | MIRUM PHARMACEUTICALS INC (US) | 2024-07-31 | — | — | EP | disclosed |
| US-20240207260-A1 | METHODS FOR TREATING CHOLESTASIS | MIRUM PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240189308-A1 | METHODS FOR TREATING CHOLESTASIS | MIRUM PHARMACEUTICALS, INC. (US) | 2024-06-13 | — | — | US | disclosed |
| CN-118139623-A | Methods of administering apical sodium-dependent cholic acid transporter inhibitors (ASBTIs) | 米鲁姆制药公司 | 2024-06-04 | — | — | CN | disclosed |
| EP-3923970-B1 | METHODS FOR INCREASING GROWTH IN PEDIATRIC SUBJECTS HAVING CHOLESTATIC LIVER DISEASE | MIRUM PHARMACEUTICALS INC (US) | 2024-05-15 | — | — | EP | disclosed |
| WO-2024098005-A1 | COMPOSITION COMPRISING GLP-1 RECEPTOR AGONIST AND ACAT INHIBITOR | EFIL BioScience Inc. (KR) | 2024-05-10 | — | — | WO | disclosed |
| US-20240148833-A1 | COMPOSITION COMPRISING GLP-1 RECEPTOR AGONIST AND ACAT INHIBITOR | EFIL BioScience Inc. (KR) | 2024-05-09 | — | — | US | disclosed |
| US-11918578-B2 | Methods for treating cholestasis | MIRUM PHARMACEUTICALS, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-11911469-B2 | Combination of ACAT1 inhibitor and checkpoint antibody for treating cancer | Center for Excellence in Molecular Cell Science, Chinese Academy of Scienes (CN) | 2024-02-27 | — | — | US | disclosed |
| US-11911469-B2 | Combination of ACAT1 inhibitor and checkpoint antibody for treating cancer | Center for Excellence in Molecular Cell Science, Chinese Academy of Scienes (CN) | 2024-02-27 | — | — | US | disclosed |
| US-11911469-B2 | Combination of ACAT1 inhibitor and checkpoint antibody for treating cancer | Center for Excellence in Molecular Cell Science, Chinese Academy of Scienes (CN) | 2024-02-27 | — | — | US | disclosed |
| US-11872198-B2 | Compositions and methods for regulating body weight and metabolic syndromes | PURDUE RESEARCH FOUNDATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-11872198-B2 | Compositions and methods for regulating body weight and metabolic syndromes | PURDUE RESEARCH FOUNDATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230302021-A1 | COMPOSITIONS AND METHODS FOR TREATING CASTRATION-RESISTANT PROSTATE CANCER | PURDUE RESEARCH FOUNDATION | 2023-09-28 | — | — | US | disclosed |
| WO-2023183843-A1 | COMBINATION THERAPY FOR TREATING CASTRATION-RESISTANT PROSTATE CANCER | PURDUE RESEARCH FOUNDATION (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-4245367-A2 | METHODS FOR TREATING CHOLESTASIS | Mirum Pharmaceuticals, Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20230285333-A1 | COMPOSITIONS AND METHODS FOR CONTROLLING FOOD INTAKE OF ANIMAL | PURDUE RESEARCH FOUNDATION | 2023-09-14 | — | — | US | disclosed |
| EP-4241840-A2 | METHODS FOR TREATING CHOLESTASIS | Mirum Pharmaceuticals, Inc. (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20230279048-A1 | COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION | 2023-09-07 | — | — | US | disclosed |
| US-20230270702-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPEPHAGIA | PURDUE RESEARCH FOUNDATION | 2023-08-31 | — | — | US | disclosed |
| US-20230270702-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPEPHAGIA | PURDUE RESEARCH FOUNDATION | 2023-08-31 | — | — | US | disclosed |
| US-20230270701-A1 | COMPOSITIONS AND METHODS FOR REDUCING SKIN FAT | PURDUE RESEARCH FOUNDATION | 2023-08-31 | — | — | US | disclosed |
| US-20230190742-A1 | METHODS FOR TREATING CHOLESTASIS | MIRUM PHARMACEUTICALS, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230138455-A1 | METHODS OF DOSING OF APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITORS (ASBTIs) | MIRUM PHARMACEUTICALS, INC. (US) | 2023-05-04 | — | — | US | disclosed |
| EP-4137137-A1 | BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS | Satiogen Pharmaceuticals, Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| US-11571400-B2 | ACAT1 inhibitors for treating cancer | CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2023-02-07 | — | — | US | disclosed |
| US-11571400-B2 | ACAT1 inhibitors for treating cancer | CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2023-02-07 | — | — | US | disclosed |
| US-11518782-B2 | Compositions containing HC-HA/PTX3 complexes and methods of use thereof | TISSUETECH, INC. (US) | 2022-12-06 | — | — | US | disclosed |
| US-20220362238-A1 | BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS | SATIOGEN PHARMACEUTICALS, INC. | 2022-11-17 | — | — | US | disclosed |
| US-11497745-B2 | Methods for treating cholestasis | MIRUM PHARMACEUTICALS, INC. (US) | 2022-11-15 | — | — | US | disclosed |
| WO-2022213878-A1 | USE OF COMPOUND RAMIPRIL TARGETING SOAT1 PROTEIN IN PREPARATION OF DRUG FOR PREVENTING AND/OR TREATING LIVER CANCER | 北京蛋白质组研究中心 | 2022-10-13 | — | — | WO | disclosed |
| US-20220265649-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-08-25 | — | — | US | disclosed |
| CN-114917345-A | Application of compound targeting SOAT1 protein in preparation of medicine for preventing and/or treating liver cancer | 北京蛋白质组研究中心 | 2022-08-19 | — | — | CN | disclosed |
| US-11376251-B2 | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| CN-114652816-A | Compositions containing HC-HA/PTX3 complexes and methods of use thereof | 组织技术公司 | 2022-06-24 | — | — | CN | disclosed |
| US-20220160726-A1 | METHODS FOR TREATING CHOLESTASIS | MIRUM PHARMACEUTICALS, INC. (US) | 2022-05-26 | — | — | US | disclosed |
| US-20220152022-A1 | METHODS FOR INCREASING GROWTH IN PEDIATRIC SUBJECTS HAVING CHOLESTATIC LIVER DISEASE | MIRUM PHARMACEUTICALS, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-20220133738-A1 | GENOTYPE AND DOSE-DEPENDENT RESPONSE TO AN ASBTI IN PATIENTS WITH BILE SALT EXPORT PUMP DEFICIENCY | MIRUM PHARMACEUTICALS, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-20220105092-A1 | METHODS FOR TREATING CHOLESTASIS | MIRUM PHARMACEUTICALS, INC. (US) | 2022-04-07 | — | — | US | disclosed |
| CN-114096268-A | Methods for increasing growth in pediatric subjects with cholestatic liver disease | 米鲁姆制药公司 | 2022-02-25 | — | — | CN | disclosed |
| CN-104619352-B | Compositions containing HC-HA/PTX3 complexes and methods of use thereof | 组织技术公司 | 2022-02-18 | — | — | CN | disclosed |
| CN-114072153-A | Methods for treating cholestasis | 米鲁姆制药公司 | 2022-02-18 | — | — | CN | disclosed |
| US-20210299073-A1 | COMPOSITIONS AND METHODS FOR REGULATING BODY WEIGHT AND METABOLIC SYNDROMES | PURDUE RESEARCH FOUNDATION | 2021-09-30 | — | — | US | disclosed |
| US-20210299074-A1 | COMPOSITIONS AND METHODS FOR REGULATING BODY WEIGHT AND METABOLIC SYNDROMES | PURDUE RESEARCH FOUNDATION | 2021-09-30 | — | — | US | disclosed |
| US-11065216-B2 | Compositions and methods for regulating body weight and metabolic syndromes | PURDUE RESEARCH FOUNDATION (US) | 2021-07-20 | — | — | US | disclosed |
| EP-3838293-A1 | COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF | Tissuetech, Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| EP-2872181-B1 | COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF | TISSUETECH INC (US) | 2020-11-18 | — | — | EP | disclosed |
| US-20200308219-A1 | COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION | 2020-10-01 | — | — | US | disclosed |
| US-10717763-B2 | Compositions containing HC-HA/PTX3 complexes and methods of use thereof | TISSUETECH, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-10597722-B2 | Predictive analysis for myocardial infarction | SCRIPPS HEALTH (US) | 2020-03-24 | — | — | US | disclosed |
| US-10596259-B2 | Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190298804-A1 | ACTIVATION OF THE ENDOGENOUS ILEAL BRAKE HORMONE PATHWAY FOR ORGAN REGENERATION AND RELATED COMPOSITIONS, METHODS OF TREATMENT, DIAGNOSTICS, AND REGULATORY SYSTEMS | VOLANT HOLDINGS GMBH (CH) | 2019-10-03 | — | — | US | disclosed |
| EP-3541426-A1 | COMPOSITIONS AND METHODS FOR REGULATING BODY WEIGHT AND METABOLIC SYNDROMES | Purdue Research Foundation (US) | 2019-09-25 | — | — | EP | disclosed |
| US-10385380-B2 | Personalized protease assay to measure protease activity in neoplasms | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-08-20 | — | — | US | disclosed |
| US-20190169231-A1 | COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION | 2019-06-06 | — | — | US | disclosed |
| US-10253065-B2 | Compositions containing HC-HA/PTX3 complexes and methods of use thereof | TISSUETECH, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20190015507-A1 | Combination of ACAT1 Inhibitor and Checkpoint Antibody for Treating Cancer | SHANGHAI INSTITUTES FOR BIOLOGICAL SCIENCES, CHINESE ACADEMY OF SCIENCES (CN) | 2019-01-17 | — | — | US | disclosed |
| US-20190015507-A1 | Combination of ACAT1 Inhibitor and Checkpoint Antibody for Treating Cancer | SHANGHAI INSTITUTES FOR BIOLOGICAL SCIENCES, CHINESE ACADEMY OF SCIENCES (CN) | 2019-01-17 | — | — | US | disclosed |
| US-20180291456-A1 | PREDICTIVE ANALYSIS FOR MYOCARDIAL INFARCTION | QUIDEL CORPORATION | 2018-10-11 | — | — | US | disclosed |
| US-10041120-B2 | Predictive analysis for myocardial infarction | SCRIPPS HEALTH (US) | 2018-08-07 | — | — | US | disclosed |
| US-10040821-B2 | Compositions containing HC-HA/PTX3 complexes and methods of use thereof | TISSUETECH, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10029017-B2 | Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-24 | — | — | US | disclosed |
| WO-2018093966-A1 | COMPOSITIONS AND METHODS FOR REGULATING BODY WEIGHT AND METABOLIC SYNDROMES | PURDUE RESEARCH FOUNDATION (US) | 2018-05-24 | — | — | WO | disclosed |
| US-20180140703-A1 | TUMOR RADIOSENSITIZATION WITH ANTIBODY CONJUGATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-05-24 | — | — | US | disclosed |
| US-9808532-B2 | Peptides whose uptake in cells is controllable | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-11-07 | — | — | US | disclosed |
| WO-2017121319-A1 | ACTIVATION OF T CELLS WITH INCREASED PLASMA MEMBRANE CHOLESTEROL LEVELS | SHANGHAI INSTITUTES FOR BIOLOGICAL SCIENCES, CHINESE ACADEMY OF SCIENCES (CN) | 2017-07-20 | — | — | WO | disclosed |
| WO-2017121318-A1 | ACAT1 INHIBITORS FOR TREATING CANCER | SHANGHAI INSTITUTES FOR BIOLOGICAL SCIENCES, CHINESE ACADEMY OF SCIENCES (CN) | 2017-07-20 | — | — | WO | disclosed |
| WO-2017121320-A1 | COMBINATION OF ACAT1 INHIBITOR AND CHECKPOINT ANTIBODY FOR TREATING CANCER | SHANGHAI INSTITUTES FOR BIOLOGICAL SCIENCES, CHINESE ACADEMY OF SCIENCES (CN) | 2017-07-20 | — | — | WO | disclosed |
| US-20170173060-A1 | ACTIVATION OF THE ENDOGENOUS ILEAL BRAKE HORMONE PATHWAY FOR ORGAN REGENERATION AND RELATED COMPOSITIONS, METHODS OF TREATMENT, DIAGNOSTICS, AND REGULATORY SYSTEMS | VOLANT HOLDINGS GMBH (CH) | 2017-06-22 | — | — | US | disclosed |
| EP-3169331-A1 | ACTIVATION OF THE ENDOGENOUS ILEAL BRAKE HORMONE PATHWAY FOR ORGAN REGENERATION AND RELATED COMPOSITIONS, METHODS OF TREATMENT, DIAGNOSTICS, AND REGULATORY SYSTEMS | Schentag, Jerome, J. (US) | 2017-05-24 | — | — | EP | disclosed |
| US-20170080088-A1 | TUMOR RADIOSENSITIZATION WITH MONOMETHYL AURISTATIN E (MMAE) AND DERIVATIVES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-23 | — | — | US | disclosed |
| US-20160376305-A1 | COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION | 2016-12-29 | — | — | US | disclosed |
| US-20160160263-A1 | PERSONALIZED PROTEASE ASSAY TO MEASURE PROTEASE ACTIVITY IN NEOPLASMS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-06-09 | — | — | US | disclosed |
| EP-3025727-A1 | METHODS OF TREATING LIVER DISEASE | The J. David Gladstone Institutes (US) | 2016-06-01 | — | — | EP | disclosed |
| US-20160095931-A1 | COMPOSITIONS CONTAINING HC-HA COMPLEX AND METHODS OF USE THEREOF | TISSUETECH, INC. | 2016-04-07 | — | — | US | disclosed |
| WO-2016011335-A1 | ACTIVATION OF THE ENDOGENOUS ILEAL BRAKE HORMONE PATHWAY FOR ORGAN REGENERATION AND RELATED COMPOSITIONS, METHODS OF TREATMENT, DIAGNOSTICS, AND REGULATORY SYSTEMS | SCHENTAG JEROME (US) | 2016-01-21 | — | — | WO | disclosed |
| US-20150359902-A1 | PRETARGETED ACTIVATABLE CELL PENETRATING PEPTIDE WITH INTRACELLULARLY RELEASABLE PRODRUG | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-12-17 | — | — | US | disclosed |
| US-20150361496-A1 | PREDICTIVE ANALYSIS FOR MYOCARDIAL INFARCTION | QUIDEL CORPORATION | 2015-12-17 | — | — | US | disclosed |
| US-20150352189-A1 | ACTIVATION OF THE ENDOGENOUS ILEAL BRAKE HORMONE PATHWAY FOR ORGAN REGENERATION AND RELATED COMPOSITIONS, METHODS OF TREATMENT, DIAGNOSTICS, AND REGULATORY SYSTEMS | DMA PATENT PARTNERS | 2015-12-10 | — | — | US | disclosed |
| WO-2015183601-A1 | PREDICTIVE ANALYSIS FOR MYOCARDIAL INFARCTION | SCRIPPS HEALTH (US) | 2015-12-03 | — | — | WO | disclosed |
| EP-2943213-A1 | ACTIVATION OF THE ENDOGENOUS ILEAL BRAKE HORMONE PATHWAY FOR ORGAN REGENERATION AND RELATED COMPOSITIONS, METHODS OF TREATMENT, DIAGNOSTICS, AND REGULATORY SYSTEMS | Schentag, Jerome (US) | 2015-11-18 | — | — | EP | disclosed |
| US-9175066-B2 | Compositions containing HC-HA complex and methods of use thereof | TISSUETECH, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| EP-2421901-B1 | COMPOSITIONS CONTAINING HC HA COMPLEX AND METHODS OF USE THEREOF | TISSUE TECH INC (US) | 2015-10-28 | — | — | EP | disclosed |
| US-20150166624-A1 | COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF | TISSUETECH, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| EP-2872181-A1 | COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF | Tissuetech, Inc. (US) | 2015-05-20 | — | — | EP | disclosed |
| CN-104619352-A | Compositions containing hc-ha/ptx3 complexes and methods of use thereof | TISSUETECH INC | 2015-05-13 | — | — | CN | disclosed |
| EP-2729802-B1 | METHOD OF ANALYZING CARDIOVASCULAR DISORDERS AND USES THEREOF | SCRIPPS HEALTH (US) | 2015-05-06 | — | — | EP | disclosed |
| US-20150098926-A1 | Methods of Treating Hepatitis C Virus Infection | THE J. DAVID GLADSTONE INSTITUTES | 2015-04-09 | — | — | US | disclosed |
| WO-2014120837-A9 | PRETARGETED ACTIVATABLE CELL PENETRATING PEPTIDE WITH INTRACELLULARY RELEASEABLE PRODRUG | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-03-26 | — | — | WO | disclosed |
| WO-2014120837-A2 | PRETARGETED ACTIVATABLE CELL PENETRATING PEPTIDE WITH INTRACELLULARY RELEASEABLE PRODRUG | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014110090-A1 | ACTIVATION OF THE ENDOGENOUS ILEAL BRAKE HORMONE PATHWAY FOR ORGAN REGENERATION AND RELATED COMPOSITIONS, METHODS OF TREATMENT, DIAGNOSTICS, AND REGULATORY SYSTEMS | SCHENTAG JEROME (US) | 2014-07-17 | — | — | WO | disclosed |
| EP-2729802-A1 | METHOD OF ANALYZING CARDIOVASCULAR DISORDERS AND USES THEREOF | Scripps Health (US) | 2014-05-14 | — | — | EP | disclosed |
| WO-2014011813-A1 | COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF | TISSUETECH, INC. (US) | 2014-01-16 | — | — | WO | disclosed |
| US-20140005096-A1 | METHODS OF TREATING INFLAMMATION | CAROLUS THERAPEUTICS, INC. (US) | 2014-01-02 | — | — | US | disclosed |
| US-8569282-B2 | Carboxamide compounds and their use | CYTOPATHFINDER, INC. (JP) | 2013-10-29 | — | — | US | disclosed |
| US-20130157347-A1 | Method of Analyzing Cardiovascular Disorders and Uses Thereof | VERIDEX, LLC (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2013006828-A1 | METHOD OF ANALYZING CARDIOVASCULAR DISORDERS AND USES THEREOF | SCRIPPS HEALTH (US) | 2013-01-10 | — | — | WO | disclosed |
| EP-2480579-A2 | METHODS OF TREATING INFLAMMATION | Carolus Therapeutics, Inc. (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20120134922-A1 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-31 | — | — | US | disclosed |
| EP-2453926-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | The Regents of the University of California (US) | 2012-05-23 | — | — | EP | disclosed |
| US-20120083445-A1 | Compositions Containing HC-HA Complex and Methods of Use Thereof | TISSUETECH, INC. (US) | 2012-04-05 | — | — | US | disclosed |
| EP-2421901-A2 | COMPOSITIONS CONTAINING HC HA COMPLEX AND METHODS OF USE THEREOF | Tissue Tech, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20110262386-A1 | METHODS OF TREATING INFLAMMATION | CAROLUS THERPEUTICS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110256130-A1 | METHODS OF TREATING INFLAMMATORY DISORDERS | SQUARE 1 BANK | 2011-10-20 | — | — | US | disclosed |
| US-20110243894-A1 | METHODS OF TREATING HEPATITIS C VIRUS INFECTION | KADMON CORPORATION, LLC | 2011-10-06 | — | — | US | disclosed |
| WO-2011116245-A2 | METHODS OF TREATING INFLAMMATION | CAROLUS THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| EP-2341924-A2 | METHODS OF TREATING HEPATITIS C VIRUS INFECTION | The J. David Gladstone Institutes (US) | 2011-07-13 | — | — | EP | disclosed |
| EP-2331564-A2 | METHODS OF TREATING INFLAMMATION | Carolus Therapeutics, Inc. (US) | 2011-06-15 | — | — | EP | disclosed |
| US-20110044988-A1 | METHODS OF TREATMENT USING ANTI-MIF ANTIBODIES | CAROLUS THERPEUTICS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| EP-2280766-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CHEMOKINE RECEPTOR AGONISTS | CytoPathfinder, Inc. (JP) | 2011-02-09 | — | — | EP | disclosed |
| WO-2011008996-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20100331298-A1 | Carboxamide Compounds and Their Use | CYTOPATHFINDER, INC. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100324035-A1 | Carboxamide Compounds and Their Use | CYTOPATHFINDER, INC. (JP) | 2010-12-23 | — | — | US | disclosed |
| WO-2010124296-A2 | COMPOSITIONS CONTAINING HC•HA COMPLEX AND METHODS OF USE THEREOF | TISSUETECH, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| US-20100226886-A1 | Combinations of MTP Inhibitors with Cholesterol Absorption Inhibitors or Interferon for Treating Hepatitis C | AEGERION PHARMACEUTICALS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100210633-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE | EPIX DELAWARE, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100184749-A1 | BENZOTHIADIAZINE COMPOUNDS AND THEIR USE | EPIX Delaware ,Inc. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100183598-A1 | METHODS OF TREATING CARDIOVASCULAR DISORDERS | CAROLUS THERAPEUTICS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| WO-2010065491-A2 | METHODS OF TREATING INFLAMMATORY DISORDERS | CAROLUS THERAPEUTICS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010056910-A2 | METHODS OF TREATING CARDIOVASCULAR DISORDERS | CAROLUS THERAPEUTICS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010042548-A2 | METHODS OF TREATING INFLAMMATION | CAROLUS THERAPEUTICS, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| US-20100093636-A1 | METHODS OF TREATING INFLAMMATION | CAROLUS THERAPEUTICS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2010039801-A2 | METHODS OF TREATING HEPATITIS C VIRUS INFECTION | THE J. DAVID GLADSTONE INSTITUTES (US) | 2010-04-08 | — | — | WO | disclosed |
| US-20090182014-A1 | INSECTICIDAL COMPOSITIONS COMPRISING COMPOUNDS HAVING INHIBITORY ACTIVITY VERSUS ACYL COA: CHOLESTEROL ACYLTRANSFERASE OR SALTS THEREOF AS EFFECTIVE INGREDIENTS | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-07-16 | — | — | US | disclosed |
| WO-2009076404-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF THE CHEMOKINE CCR2 RECEPTOR | EPIX DELAWARE, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009076512-A1 | CARBOXAMIDΞ COMPOUNDS AND THEIR USE AS CHEMOKINE RECEPTOR AGONISTS | EPIX DELAWARE, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2008124384-A2 | COMBINATIONS OF MTP INHIBITORS WITH CHOLESTEROL ABSORPTION INHIBITORS OR INTERFERON FOR TREATING HEPATITIS C | AEGERION PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20080253985-A1 | Compositions for Lowering Serum Cholesterol and/or Triglycerides | AEGERION PHARMACEUTICALS, INC. | 2008-10-16 | — | — | US | disclosed |
| US-7414066-B2 | Amide compounds and medications containing the same technical field | KOWA COMPANY LTD. (JP) | 2008-08-19 | — | — | US | disclosed |
| EP-1945205-A2 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL | Aegerion Pharmaceuticals (US) | 2008-07-23 | — | — | EP | disclosed |
| US-7393866-B2 | Amide compounds and medications containing the same | KOWA COMPANY, LTD. (JP) | 2008-07-01 | — | — | US | disclosed |
| WO-2008045558-A2 | BENZOTHIADIAZINE COMPOUNDS AND THEIR USE | EPIX DELAWARE, INC. (US) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008045564-A2 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF THE CHEMOKINE CCR2 RECEPTOR | EPIX DELAWARE, INC. (US) | 2008-04-17 | — | — | WO | disclosed |
| WO-2007047880-A2 | COMPOSITIONS FOR LOWERING SERUM CHOLESTEROL AND/OR TRIGLYCERIDES | AEGERION PHARMACEUTICALS (US) | 2007-04-26 | — | — | WO | disclosed |
| EP-0858336-B1 | METHOD AND PHARMACEUTICAL COMPOSITION FOR REGULATING LIPID CONCENTRATION | WARNER LAMBERT CO (US) | 2006-12-20 | — | — | EP | disclosed |
| EP-0979823-B1 | NOVEL AMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | KOWA CO (JP) | 2006-03-29 | — | — | EP | disclosed |
| EP-0807627-B1 | Anilide compounds as ACAT inhibitors | KOWA CO (JP) | 2005-12-28 | — | — | EP | disclosed |
| US-6969711-B2 | Cyclic diamine compounds and medicine containing the same | KOWA COMPANY, LTD. (JP) | 2005-11-29 | — | — | US | disclosed |
| US-20050234124-A1 | Carboxyalkylether-ACAT inhibitor combinations | AUERBACH BRUCE J | 2005-10-20 | — | — | US | disclosed |
| US-20050234090-A1 | Modulators of chemokine receptor activity | PFIZER INC | 2005-10-20 | — | — | US | disclosed |
| CN-1679953-A | Pharmaceutical composition for regulating lipid concentration | WARNER LAMBERT CO (US) | 2005-10-12 | — | — | CN | disclosed |
| CN-1217656-C | Methods and pharmaceutical compositions for modulating lipid concentrations | WARNER LAMBERT CO (US) | 2005-09-07 | — | — | CN | disclosed |
| US-20050131002-A1 | Novel amide compounds and medications containing the same | KOWA COMPANY LTD. (JP) | 2005-06-16 | — | — | US | disclosed |
| US-20050131001-A1 | Novel amide compounds and medications containing the same technical field | KOWA COMPANY LTD. (JP) | 2005-06-16 | — | — | US | disclosed |
| EP-1020451-B1 | ANILIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | KOWA CO (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-20050118226-A1 | Sustained-release implant releases ACAT inhibitor for a time effective to reduce ACAT activity; Alzheimer's disease, atherosclerosis; amyloid- beta reduction | GENERAL HOSPITAL CORPORATION, THE | 2005-06-02 | — | — | US | disclosed |
| EP-1263421-B1 | THE DUAL INHIBITOR OF CHOLESTERYL ESTER AND WAX ESTER SYNTHESIS AVASIMIBE FOR TREATING SEBACEOUS GLAND DISORDERS | WARNER LAMBERT CO (US) | 2005-05-18 | — | — | EP | disclosed |
| US-6849647-B1 | Amide compounds and medications containing the same technical field | KOWA COMPANY, LTD. (JP) | 2005-02-01 | — | — | US | disclosed |
| EP-0987254-B1 | NOVEL CYCLIC DIAMINE COMPOUNDS AND MEDICINE CONTAINING THE SAME | KOWA CO (JP) | 2004-12-22 | — | — | EP | disclosed |
| US-6825223-B2 | ACYL COENZYME A CHOLESTEROL ACYLTRANSFERASE (ACAT) INHIBITORS; 2-SUBSTITUTED BENZIMIDAZOLE, BENZOXAZOLE, AND BENZOTHIAZOLES | KOWA COMPANY, LTD. (JP) | 2004-11-30 | — | — | US | disclosed |
| US-6821964-B2 | FOR PROPHYLAXIS AND THERAPY OF DISEASES ASSOCIATED WITH MONOCYTE ACCUMULATION, LYMPHOCYTE ACCUMULATION OR LEUCOCYTE ACCUMULATION | PFIZER INC | 2004-11-23 | — | — | US | disclosed |
| US-6797717-B2 | ACYL COENZYME A CHOLESTEROL ACYLTRANSFERASE (ACAT) INHIBITORS | KOWA COMPANY, LTD. (JP) | 2004-09-28 | — | — | US | disclosed |
| US-20040161393-A1 | Dual inhibitors of cholesteryl ester and wax ester synthesis for sebaceous gland disorders | HOMAN REYNOLD (US) | 2004-08-19 | — | — | US | disclosed |
| EP-1431294-A1 | VASCULAR WALL-SELECTIVE ACAT INHIBITOR | Kowa Company Ltd. (JP) | 2004-06-23 | — | — | EP | disclosed |
| US-6730703-B2 | ADMINISTERING AN EFFECTIVE AMOUNT OF ((2,4,6-TRIISOPROPYL-PHENYL)-ACETYL)-SULFAMIC ACID 2,6-DIISO-PROPYL-PHENYL ESTER OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; ACNE | WARNER-LAMBERT COMPANY | 2004-05-04 | — | — | US | disclosed |
| US-20040072903-A1 | Carboxyalkylether-acat inhibitors combinations | AUERBACH BRUCE JEFFREY (US) | 2004-04-15 | — | — | US | disclosed |
| US-20040038987-A1 | Novel cyclic diamine compounds and medicine containing the same | KOWA COMPANY, LTD. (JP) | 2004-02-26 | — | — | US | disclosed |
| EP-1368354-A1 | MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Pfizer Products Inc. (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20030087928-A1 | Novel anilide compounds and drugs containing the same | KOWA COMPANY, LTD., JAPAN | 2003-05-08 | — | — | US | disclosed |
| US-20030060507-A1 | Dual inhibitors of cholesteryl ester and wax ester synthesis for sebaceous gland disorders | HOMAN REYNOLD (US) | 2003-03-27 | — | — | US | disclosed |
| EP-1292363-A2 | CARBOXYALKYLETHER-ACAT INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 2003-03-19 | — | — | EP | disclosed |
| US-6534521-B2 | Useful in the treatment of inflammation, atherosclerosis, restenosis, and immune disorders such as arthritis and transplant rejection | MILLENNIUM PHARMACEUTICALS, INC. | 2003-03-18 | — | — | US | disclosed |
| US-20030008893-A1 | Modulators of chemokine receptor activity | COLON-CRUZ ROBERTO (US) | 2003-01-09 | — | — | US | disclosed |
| EP-1263421-A2 | THE DUAL INHIBITOR OF CHOLESTERYL ESTER AND WAX ESTER SYNTHESIS AVASIMIBE FOR TREATING SEBACEOUS GLAND DISORDERS | Warner-Lambert Company LLC (US) | 2002-12-11 | — | — | EP | disclosed |
| US-6458806-B1 | ANTIINFLAMMATORY AND -ARTHRITIC AGENTS, ATHEROSCLEROSIS, RESTENOSIS; TRANSPLANT REJECTION; INFLAMMATORY BOWEL DISEASES, CROHN'S DISEASE, ANTIALLERGENS; IMMUNE, SKIN GASTROINTESTINAL AND RESPIRATORY SYSTEM DIORDERS | MILLENNIUM PHARMACEUTICALS, INC. | 2002-10-01 | — | — | US | disclosed |
| WO-2002070523-A1 | MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | PFIZER PRODUCTS INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| US-20020099054-A1 | 2-phenyl benzimidazole derivatives as MCP-1 antagonists | WARNER-LAMBERT COMPANY (US) | 2002-07-25 | — | — | US | disclosed |
| US-20020099074-A1 | Novel anilide compounds and drugs containing the same | KOWA COMPANY, LTD.,JAPAN | 2002-07-25 | — | — | US | disclosed |
| US-20020037910-A1 | Novel anilide compounds and pharmaceutical compositions comprising them | SHIBUYA KIMIYUKI (JP) | 2002-03-28 | — | — | US | disclosed |
| US-6362208-B1 | ANTICHOLESTEROL AGENT | KOWA COMPANY, LTD. (JP) | 2002-03-26 | — | — | US | disclosed |
| US-20020028833-A1 | ARYL ALKENAMIDES DERIVATIVES AS MCP-1 ANTAGONISTS | MILLENNIUM PHARMACEUTICALS, INC. | 2002-03-07 | — | — | US | disclosed |
| US-6348487-B1 | ANTIINFLAMMATORY AGENTS, ATHEROSCLEROSIS, RESTINOSIS AND IMMUNE DISORDERS | MILLENNIUM PHARMACEUTICALS, INC. | 2002-02-19 | — | — | US | disclosed |
| WO-2001093845-A2 | CARBOXYALKYLETHER-ACAT INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 2001-12-13 | — | — | WO | disclosed |
| US-20010018427-A1 | Method of using a scavenger receptor in the treatment of atherosclerosis | WARNER-LAMBERT COMPANY (US) | 2001-08-30 | — | — | US | disclosed |
| WO-2001056556-A2 | DUAL INHIBITORS OF CHOLESTERYL ESTER AND WAX ESTER SYNTHESIS FOR SEBACEOUS GLAND DISORDERS | WARNER-LAMBERT COMPANY (US) | 2001-08-09 | — | — | WO | disclosed |
| US-6204278-B1 | Anilide compounds, including use thereof in ACAT inhibitition | KOWA COMPANY, LTD. (JP) | 2001-03-20 | — | — | US | disclosed |
| US-6184235-B1 | MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1) ANTAGONIST FOR TREATMENT OF INFLAMMATORY DISEASES, ATHEROSCLEROSIS, RESTENOSIS, AUTOIMMUNE DISEASES, ORGAN TRANSPLANT REJECTION IN MAMMALS | WARNER-LAMBERT COMPANY | 2001-02-06 | — | — | US | disclosed |
| US-6143755-A | DRUGS FOR RESTORATION OF ENDOGENOUS VASCULAR ACTIVITIES AS ANTICOAGULANTS AND VASODILATION | WARNER-LAMBERT COMPANY (US) | 2000-11-07 | — | — | US | disclosed |
| US-6124309-A | ADMINISTERING ACYLCOENZYME A:CHOLESTEROL ACYLTRANSFERASE INHIBITOR AND HYDROXY-3-METHYLGLUTARYL/3-/ COENZYME A REDUCTASE INHIBITOR | WARNER-LAMBERT COMPANY (US) | 2000-09-26 | — | — | US | disclosed |
| US-6093719-A | ADMINISTERING THERAPEUTICALLY EFFECTIVE AMOUNTS OF ACYL-COA CHOLESTEROL O-ACYLTRANSFERASE (ACAT) INHIBITOR AND AN HMG-COA REDUCTASE INHIBITOR; FOR PATIENTS WITH OR AT RISK OF DEVELOPING ISCHEMIC SYNDROMES | WARNER-LAMBERT COMPANY (US) | 2000-07-25 | — | — | US | disclosed |
| EP-1020451-A1 | NOVEL ANILIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | Kowa Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
| EP-0874812-B1 | NOVEL 2,3,5-TRIMETHYL-4-HYDROXY ANILIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTICAL USE THEREOF | PF MEDICAMENT (FR) | 2000-04-05 | — | — | EP | disclosed |
| EP-0987254-A1 | NOVEL CYCLIC DIAMINE COMPOUNDS AND MEDICINE CONTAINING THE SAME | Kowa Co., Ltd. (JP) | 2000-03-22 | — | — | EP | disclosed |
| EP-0979823-A1 | NOVEL AMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | Kowa Company Ltd. (JP) | 2000-02-16 | — | — | EP | disclosed |
| US-6011052-A | Pyrazolone derivatives as MCP-1 antagonists | WARNER-LAMBERT COMPANY (US) | 2000-01-04 | — | — | US | disclosed |
| US-5958950-A | CARDIOVASCULAR DISORDERS | WARNER-LAMBERT COMPANY (US) | 1999-09-28 | — | — | US | disclosed |
| EP-0927167-A1 | 2-PHENYL BENZIMIDAZOLE DERIVATIVES AS MCP-1 ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-07-07 | — | — | EP | disclosed |
| US-5872115-A | COMPOUNDS FOR TREATMENT OF HYPERCHOLESTEROLEMIA, ISCHEMIC HEART DISEASE, CEREBROVASCULAR DISEASE OR ATHEROSCLEROSIS | GRELAN PHARMACEUTICAL CO. LTD. (JP) | 1999-02-16 | — | — | US | disclosed |
| CN-1201389-A | Methods and pharmaceutical compositions for modulating lipid concentrations | WARNER LAMBERT CO (US) | 1998-12-09 | — | — | CN | disclosed |
| EP-0858336-A1 | METHOD AND PHARMACEUTICAL COMPOSITION FOR REGULATING LIPID CONCENTRATION | WARNER-LAMBERT COMPANY (US) | 1998-08-19 | — | — | EP | disclosed |
| US-5747528-A | Chroman derivatives as anti-oxidants | WARNER-LAMBERT COMPANY (US) | 1998-05-05 | — | — | US | disclosed |
| WO-1998006703-A1 | 2-PHENYL BENZIMIDAZOLE DERIVATIVES AS MCP-1 ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-02-19 | — | — | WO | disclosed |
| EP-0807627-A2 | Anilide compounds as ACAT inhibitors | Kowa Company Ltd. (JP) | 1997-11-19 | — | — | EP | disclosed |
| EP-0784681-A1 | METHOD OF USING A SCAVENGER RECEPTOR IN THE TREATMENT OF ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1997-07-23 | — | — | EP | disclosed |
| WO-1997016184-A1 | METHOD AND PHARMACEUTICAL COMPOSITION FOR REGULATING LIPID CONCENTRATION | WARNER-LAMBERT COMPANY (US) | 1997-05-09 | — | — | WO | disclosed |
| WO-1997012615-A1 | BENZIMIDAZOLE DERIVATIVES AS 15-LO INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1997-04-10 | — | — | WO | disclosed |
| WO-1996011268-A1 | METHOD OF USING A SCAVENGER RECEPTOR IN THE TREATMENT OF ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1996-04-18 | — | — | WO | disclosed |
| EP-0680472-A1 | 4,5-DIPHENYLIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ACYL COENZYME A: CHOLESTEROL-0-ACYL-TRANSFERASE (ACAT) INHIBITOR | PHARMACIA & UPJOHN S.p.A. (IT) | 1995-11-08 | — | — | EP | disclosed |
| WO-1995014673-A1 | 4,5-DIPHENYLIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ACYL COENZYME A: CHOLESTEROL-0-ACYL-TRANSFERASE (ACAT) INHIBITOR | PHARMACIA S.P.A. (IT) | 1995-06-01 | — | — | WO | disclosed |
| US-5416212-A | Antilipemic agents, enzyme inhibitors and anticholesterol agents | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1995-05-16 | — | — | US | disclosed |
| EP-0619312-A1 | ANILIDE DERIVATIVE | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1994-10-12 | — | — | EP | disclosed |
| US-5254590-A | Enzyme inhibitors, anticholesterol, treatment of atheroscherosis, dylipidemias | ADIR ET COMPAGNIE (FR) | 1993-10-19 | — | — | US | disclosed |
| EP-0508842-A1 | Aminoacylphenol derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1992-10-14 | — | — | EP | disclosed |
| US-4743605-A | PREVENT ABSORPTION OF CHOLESTEROL | WARNER-LAMBERT COMPANY (US) | 1988-05-10 | — | — | US | disclosed |
| US-4716175-A | INHIBITION OF INTESTINAL ABSORPTION OF CHOLESTEROL | WARNER-LAMBERT COMPANY (US) | 1987-12-29 | — | — | US | disclosed |
| US-4716175-A | INHIBITION OF INTESTINAL ABSORPTION OF CHOLESTEROL | WARNER-LAMBERT COMPANY (US) | 1987-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331298-A1 | Carboxamide Compounds and Their Use | CCR2, CCR1, CCR5 | KDM4E 3492/4885TP53 4563/4885CYP3A4 1097/4885 |
| US-10029017-B2 | Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug | DNPEP, FOLH1, CTSL | KDM4E 4500/4885TP53 368/4885CYP3A4 4742/4885 |
| US-20020028833-A1 | ARYL ALKENAMIDES DERIVATIVES AS MCP-1 ANTAGONISTS | CCR2, CCR1, MSR1 | KDM4E 3138/4885TP53 3652/4885CYP3A4 1048/4885 |
| US-11065216-B2 | Compositions and methods for regulating body weight and metabolic syndromes | ACAT1, ACAT2, ACACA | KDM4E 2703/4885TP53 4868/4885CYP3A4 2046/4885 |
| US-20110243894-A1 | METHODS OF TREATING HEPATITIS C VIRUS INFECTION | HAVCR2, LIPC, FABP1 | KDM4E 2296/4885TP53 3956/4885CYP3A4 2164/4885 |
| US-20100226886-A1 | Combinations of MTP Inhibitors with Cholesterol Absorption Inhibitors or Interferon for Treating Hepatitis C | CETP, MTTP, LIPC | KDM4E 4125/4885TP53 3588/4885CYP3A4 257/4885 |
| US-20250281482-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | SLC10A1, SLC10A2, ABCB11 | KDM4E 3989/4885TP53 4643/4885CYP3A4 667/4885 |
| US-20210299074-A1 | COMPOSITIONS AND METHODS FOR REGULATING BODY WEIGHT AND METABOLIC SYNDROMES | ACAT1, ACAT2, ACACA | KDM4E 2703/4885TP53 4868/4885CYP3A4 2046/4885 |
| US-11571400-B2 | ACAT1 inhibitors for treating cancer | ACAT2, ACAT1, CEPT1 | KDM4E 272/4885TP53 102/4885CYP3A4 3051/4885 |
| US-20240189308-A1 | METHODS FOR TREATING CHOLESTASIS | SLC10A1, SLC10A2, NR1H4 | KDM4E 4429/4885TP53 4809/4885CYP3A4 1382/4885 |
| US-20050131001-A1 | Novel amide compounds and medications containing the same technical field | ACAT2, SULT2A1, ACAT1 | KDM4E 1007/4885TP53 3624/4885CYP3A4 84/4885 |
| US-20090182014-A1 | INSECTICIDAL COMPOSITIONS COMPRISING COMPOUNDS HAVING INHIBITORY ACTIVITY VERSUS ACYL COA: CHOLESTEROL ACYLTRANSFERASE OR SALTS THEREOF AS EFFECTIVE INGREDIENTS | ACAT2, LCAT, ACAT1 | KDM4E 2528/4885TP53 4700/4885CYP3A4 313/4885 |
| US-20030060507-A1 | Dual inhibitors of cholesteryl ester and wax ester synthesis for sebaceous gland disorders | HMGCR, DHCR7, HSD3B1 | KDM4E 3411/4885TP53 1382/4885CYP3A4 1583/4885 |
| US-11376251-B2 | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases | SLC10A1, SLC10A2, ABCB11 | KDM4E 3989/4885TP53 4643/4885CYP3A4 667/4885 |
| US-12350267-B2 | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases | SLC10A1, SLC10A2, ABCB11 | KDM4E 3989/4885TP53 4643/4885CYP3A4 667/4885 |
| US-20250282808-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE | SLC10A1, SLC10A2, ABCB11 | KDM4E 4592/4885TP53 4556/4885CYP3A4 1274/4885 |
| US-20030087928-A1 | Novel anilide compounds and drugs containing the same | ACAT1, ACAT2, LCAT | KDM4E 450/4885TP53 4860/4885CYP3A4 124/4885 |
| US-11911469-B2 | Combination of ACAT1 inhibitor and checkpoint antibody for treating cancer | CD274, PDCD1, PDCD4 | KDM4E 386/4885TP53 167/4885CYP3A4 3867/4885 |
| US-20220105092-A1 | METHODS FOR TREATING CHOLESTASIS | SLC10A1, SLC10A2, NR1H4 | KDM4E 4429/4885TP53 4809/4885CYP3A4 1382/4885 |
| US-20220152022-A1 | METHODS FOR INCREASING GROWTH IN PEDIATRIC SUBJECTS HAVING CHOLESTATIC LIVER DISEASE | SLC10A1, SLC10A2, FABP1 | KDM4E 4132/4885TP53 4564/4885CYP3A4 2591/4885 |
| US-20230190742-A1 | METHODS FOR TREATING CHOLESTASIS | SLC10A1, SLC10A2, ABCB11 | KDM4E 4394/4885TP53 4807/4885CYP3A4 1252/4885 |
| US-12257217-B2 | Compositions and methods for treating hyperphagia in prader-willi syndrome | ACAT2, ACAT1, LCAT | KDM4E 3367/4885TP53 4626/4885CYP3A4 3687/4885 |
| US-20100210633-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE | CCR2, CCR1, CCR5 | KDM4E 3492/4885TP53 4563/4885CYP3A4 1097/4885 |
| US-20020099054-A1 | 2-phenyl benzimidazole derivatives as MCP-1 antagonists | CCR1, CCR2, CCR8 | KDM4E 2846/4885TP53 3756/4885CYP3A4 1292/4885 |
| US-12274681-B2 | Compositions and methods for reducing skin fat | ACAT1, ACAT2, ACACA | KDM4E 1594/4885TP53 4855/4885CYP3A4 1885/4885 |
| US-10596259-B2 | Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof | AURKA, AURKB, MMAB | KDM4E 625/4885TP53 232/4885CYP3A4 4832/4885 |
| US-20080253985-A1 | Compositions for Lowering Serum Cholesterol and/or Triglycerides | CETP, LCAT, HMGCR | KDM4E 4182/4885TP53 4471/4885CYP3A4 754/4885 |
| US-20020037910-A1 | Novel anilide compounds and pharmaceutical compositions comprising them | ACAT1, LCAT, SOAT1 | KDM4E 785/4885TP53 4770/4885CYP3A4 347/4885 |
| US-20100184749-A1 | BENZOTHIADIAZINE COMPOUNDS AND THEIR USE | CCR2, CCR5, CCR1 | KDM4E 4818/4885TP53 3492/4885CYP3A4 1443/4885 |
| US-20240207260-A1 | METHODS FOR TREATING CHOLESTASIS | SLC10A1, SLC10A2, NR1H4 | KDM4E 4429/4885TP53 4809/4885CYP3A4 1382/4885 |
| US-11872198-B2 | Compositions and methods for regulating body weight and metabolic syndromes | ACAT1, ACAT2, ACACA | KDM4E 2703/4885TP53 4868/4885CYP3A4 2046/4885 |
| US-20020099074-A1 | Novel anilide compounds and drugs containing the same | SOAT1, SOAT2, LCAT | KDM4E 579/4885TP53 4777/4885CYP3A4 104/4885 |
| US-12599602-B2 | Methods for treating cholestasis | SLC10A1, SLC10A2, SLC10A6 | KDM4E 3552/4885TP53 4536/4885CYP3A4 1673/4885 |
| US-20040161393-A1 | Dual inhibitors of cholesteryl ester and wax ester synthesis for sebaceous gland disorders | HMGCR, DHCR7, HSD11B2 | KDM4E 3444/4885TP53 1351/4885CYP3A4 1619/4885 |
| US-20210299073-A1 | COMPOSITIONS AND METHODS FOR REGULATING BODY WEIGHT AND METABOLIC SYNDROMES | ACAT1, ACAT2, ACACA | KDM4E 2703/4885TP53 4868/4885CYP3A4 2046/4885 |
| US-20150098926-A1 | Methods of Treating Hepatitis C Virus Infection | HAVCR2, LIPC, FABP1 | KDM4E 2296/4885TP53 3956/4885CYP3A4 2164/4885 |
| US-20230270702-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPEPHAGIA | ACAT2, ACAT1, LCAT | KDM4E 2108/4885TP53 4883/4885CYP3A4 2399/4885 |
| US-20170080088-A1 | TUMOR RADIOSENSITIZATION WITH MONOMETHYL AURISTATIN E (MMAE) AND DERIVATIVES THEREOF | AURKA, AURKB, MMAB | KDM4E 625/4885TP53 232/4885CYP3A4 4832/4885 |
| US-20220265649-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | SLC10A1, SLC10A2, ABCB11 | KDM4E 3989/4885TP53 4643/4885CYP3A4 667/4885 |
| US-20110256130-A1 | METHODS OF TREATING INFLAMMATORY DISORDERS | TNF, MPO, MMP8 | KDM4E 2986/4885TP53 4070/4885CYP3A4 3418/4885 |
| US-20150359902-A1 | PRETARGETED ACTIVATABLE CELL PENETRATING PEPTIDE WITH INTRACELLULARLY RELEASABLE PRODRUG | DNPEP, FOLH1, CTSL | KDM4E 4500/4885TP53 368/4885CYP3A4 4742/4885 |
| US-20040072903-A1 | Carboxyalkylether-acat inhibitors combinations | LCAT, CETP, ACAT2 | KDM4E 1299/4885TP53 4026/4885CYP3A4 971/4885 |
| US-20030008893-A1 | Modulators of chemokine receptor activity | CCR1, CCR3, CCR2 | KDM4E 4790/4885TP53 4117/4885CYP3A4 2899/4885 |
| US-20220133738-A1 | GENOTYPE AND DOSE-DEPENDENT RESPONSE TO AN ASBTI IN PATIENTS WITH BILE SALT EXPORT PUMP DEFICIENCY | SLC10A1, ABCB11, SLC10A2 | KDM4E 4686/4885TP53 4317/4885CYP3A4 784/4885 |
| US-20230270701-A1 | COMPOSITIONS AND METHODS FOR REDUCING SKIN FAT | ACAT1, ACAT2, ACACA | KDM4E 1594/4885TP53 4855/4885CYP3A4 1885/4885 |
| US-12576079-B2 | Methods for treating cholestasis | SLC10A1, SLC10A2, SLC10A6 | KDM4E 3073/4885TP53 4660/4885CYP3A4 2369/4885 |
| US-20100183598-A1 | METHODS OF TREATING CARDIOVASCULAR DISORDERS | TNNI3, TNNT2, FABP3 | KDM4E 825/4885TP53 4859/4885CYP3A4 2784/4885 |
| US-20050234124-A1 | Carboxyalkylether-ACAT inhibitor combinations | LCAT, CETP, ACAT2 | KDM4E 1507/4885TP53 2902/4885CYP3A4 1750/4885 |
| US-20220362238-A1 | BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS | SLC10A2, GPR119, GPBAR1 | KDM4E 4773/4885TP53 4665/4885CYP3A4 2318/4885 |
| US-20220160726-A1 | METHODS FOR TREATING CHOLESTASIS | SLC10A1, SLC10A2, NR1H4 | KDM4E 4429/4885TP53 4809/4885CYP3A4 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.